title: Mantle cell lymphoma-management in evolution.
abstract: The management of mantle cell lymphoma (MCL) has been an area of rapid change in recent years. These changes have improved the prognosis for a disease that has had historically poor outcomes. There are several treatment options for the patient with newly diagnosed MCL, with younger, fit patients often receiving intensive treatment, while less intensive strategies have been used for older, less fit patients. The past few years has also seen the arrival of several novel agents used in the treatment of patients with relapsed/refractory (R/R) disease. These targeted therapies combine relatively high response rates with a favorable side-effect profile making them ideal agents for use in this patient population.
authors.affiliation: Department of Medicine, Division of Hematology/Oncology, University of Wisconsin School of Medicine and Public Health and the UW Carbone Cancer Center, University of Wisconsin, Madison, WI, USA.
authors.forename: Saurabh
authors.initials: S
authors.lastname: Rajguru
authors.affiliation: Department of Medicine, Division of Hematology/Oncology, University of Wisconsin School of Medicine and Public Health and the UW Carbone Cancer Center, University of Wisconsin, Madison, WI, USA. bsk@medicine.wisc.edu.
authors.forename: Brad S
authors.initials: BS
authors.lastname: Kahl
mesh_terms: D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality / Q000473:pathology; D058990:Molecular Targeted Therapy; D018579:Patient Selection; D012008:Recurrence; D012307:Risk Factors; D015398:Signal Transduction / Q000187:drug effects; D013997:Time Factors; D016896:Treatment Outcome; D057832:Watchful Waiting
keywords: Mantle cell lymphoma (MCL); therapy